ArticleOncotarget2018
Circulating tumour-derived DNA in metastatic soft tissue sarcoma.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Investigating the Use of Circulating Tumor DNA for Sarcoma Management.Journal of clinical medicine · 2024Article
- Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents.Frontiers in pediatrics · 2022Article
- Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?Frontiers in oncology · 2022Review
- Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?Biomedicines · 2021Review
- Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas.Bone & joint research · 2021Article
- Review
- Molecular profiling of soft-tissue sarcomas with FoundationOneTherapeutic advances in medical oncology · 2021Article
- Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers.Frontiers in oncology · 2021Article
- Sarcoma treatment in the era of molecular medicine.EMBO molecular medicine · 2020Review
- The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients.International journal of molecular sciences · 2020Article
- Multidisciplinary treatment of soft tissue sarcomas: An update.World journal of clinical oncology · 2020Review
- Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?Current oncology reports · 2020Review
- Circulating tumor DNA analysis in the era of precision oncology.Oncotarget · 2020Review
- A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA.Frontiers in oncology · 2020Article
- The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids.Journal of Cancer · 2020Review
- Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter.Scientific reports · 2019Article
- Article
- Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Following treatment 40% of soft tissue sarcoma (STS) patients suffer disease recurrence. In certain cancers circulating cell free DNA (cfDNA) and circulating tumour-derived DNA (ctDNA) characteristics correlate closely with disease burden, making them exciting potential sources of biomarkers. Despite this, the circulating nucleic acid characteristics of only 2 STS patients have been reported to date. To address this we used an Ion AmpliSeq™ panel custom specifically designed for STS patients to conduct a genetic characterisation of plasma cfDNA, buffy coat (germline) DNA and where available Formalin-Fixed Paraffin-Embedded (FFPE) primary STS tissue DNA in a cohort of 11 metastatic STS patients. We found that total cfDNA levels were significantly elevated in the STS patients analysed, and weakly correlated with disease burden. Using our Ion AmpliSeq™ panel we also successfully detected ctDNA in 4/11 (36%) patients analysed with a wide variety of STS subtypes and disease burdens. This evidence included the presence of cancer associated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.